(M2 PressWIRE Via Acquire Media NewsEdge) BUYINS.NET / www.squeezetrigger.com is monitoring the performance of all stocks with earnings being released in the coming weeks and determining how the stocks have performed Before their last 12 quarterly, 6 quarterly and December earnings reports. Chyron Corp (NASDAQ:CHYR), Celldex Therapeutics Inc (NASDAQ:CLDX), Furmanite Corp (NYSE:FRM), Gerdau SA (NYSE:GGB), Auxilium Pharmaceuticals Inc (NASDAQ:AUXL), Momenta Pharmaceuticals Inc (NASDAQ:MNTA) are all expected to be Down Before their earnings are released. The movement of stock prices in the days and weeks leading to and following these earnings announcements may follow a predictable pattern. Most companies stock price histories show random or unpredictable movements around earnings dates. But some seem to repeat the same pattern quarter after quarter, year after year. The # of Reports in the table below shows how many previous quarterly reports comprise the indicator that predicts how a stock will act after its earnings are released. The specific technology used to make these predictions is available for a low monthly fee at http://www.squeezetrigger.com/services/strat/mh.php . The following stocks are expected to go Down Before earnings are released Thursday:
Symbol Company # of Reports Quarter Release Date
CHYR Chyron Corp 12 Quarter Q4 03/07/2013
CLDX Celldex Therapeutics Inc 6 Quarter Q4 03/07/2013
FRM Furmanite Corp 6 Quarter Q4 03/05/2013
GGB Gerdau SA 6 Quarter Q4 02/21/2013
AUXL Auxilium Pharmaceuticals Inc 6 Quarter Q4 02/21/2013
MNTA Momenta Pharmaceuticals Inc 6 Quarter Q4 02/15/2013
This technology is designed to help the stock trader identify those companies that seem to have a consistent pattern of movement before or after the earnings release date, based on the history of earnings releases for that company. It combines a calendar of expected earnings releases with a history of past earnings releases in a way that lets you see if a pattern exists.
Chyron Corp (NASDAQ:CHYR) - Chyron Corporation develops, manufactures, markets, and supports hardware and software products that are designed to provide broadcast-quality graphics and audio for live and pre-recorded productions and to enhance workflow and video asset management for broadcast operations. Its graphics solutions include the Axis World Graphics (Axis) online content creation software and order management system, on-air graphics systems, clip servers, channel branding, and graphics asset management solutions. The company s graphics products provide broadcast-quality, real-time, HD/SD, 2D/3D, graphics creation and playout for television stations, networks, video production, and post-production markets. Its hardware products include HyperX3.1, LEX3.1, and MicroX3, which are 2D/3D graphics platforms and systems that integrate a Windows front end with real-time video processing; Channel Box systems that features 2D/3D design and playout for branding applications; and XClyps, XClyps SAN, and MicroClyps systems for providing quality and control over graphics playout. The company also provides Axis World Graphics, cloud-based graphics creation system, designed specifically for broadcasters; and Axis order management systems to the specifications of a select group of its high-profile clients. In addition, it offers software products, such as Lyric, an advanced graphics creation and playback application; and Lyric PRO for graphics creation and real-time live playout application. Further, it provides newsroom integration and graphics/video asset management products; BlueNet, an end-to-end workflow solution; and graphic design, technical, and support and training services. The company was formerly known as The Computer Exchange, Inc. and changed its name to Chyron Corporation in November 1975. Chyron Corporation was founded in 1966 and is headquartered in Melville, New York..
Celldex Therapeutics Inc (NASDAQ:CLDX) - Celldex Therapeutics, Inc., a biopharmaceutical company, focuses on the development, manufacture, and commercialization of novel therapeutics for human health care primarily in the United States. The company markets Rotarix to treat rotavirus infection. Its lead drug candidate, rindopepimut (CDX-110), is an immunotherapeutic vaccine in Phase III clinical trial to target the tumor-specific molecule, epidermal growth factor receptor variant III, as well as in Phase II clinical trial for the indication of recurrent glioblastoma. The company s other lead drug candidates comprise CDX-011, an antibody-drug conjugate in Phase IIb clinical trial for metastatic breast cancer and melanoma indication; and CDX-1127, a human monoclonal antibody in Phase I clinical trial for the treatment of lymphoma/leukemia and solid tumors. Its additional clinical and preclinical programs consist of CDX-1401, an Antigen Presenting Cells Targeting Technology program in Phase I/II clinical trial to treat multiple solid tumors; and CDX-301, an immune cell mobilizing agent and dendritic cell growth factor in Phase I clinical for treating cancer, autoimmune disease, and transplant. The company s preclinical products include CDX-1135, a molecule for treating renal disease; and CDX-014, a human monoclonal antibody-drug conjugate for the treatment of ovarian and renal cancer. It has research collaboration and license agreements with Medarex, Inc.; Rockefeller University; Duke University Brain Tumor Cancer Center; Ludwig Institute for Cancer Research; Alteris Therapeutics, Inc.; Thomas Jefferson University; 3M Company; University of Southampton; Amgen Inc.; Amgen Fremont; and Seattle Genetics, Inc. Celldex Therapeutics, Inc. was founded in 1983 and is headquartered in Needham, Massachusetts..
Furmanite Corp (NYSE:FRM) - Furmanite Corporation, through its subsidiaries, provides technical services in Europe, North America, South America, Latin America, the Middle East, Africa, and the Asia Pacific. It provides on-line repairs of leaks in valves, pipes, and other components of piping systems and related equipment used in flow-process industries; and hot tapping, line stopping, line isolation, composite repair, and valve testing services. The company also provides off-line services, including on-site machining, heat treatment, and bolting and valve repair; and smart shim services, concrete repair, engineering services, valve and other products, and manufacturing. In addition, it performs diagnostic services on valves utilizing its patented Trevitest system. The company offers its products and services primarily to electric power generating plants; petroleum industry, including refineries and off-shore drilling rigs; and chemical plants, pipelines, offshore drilling and production platforms, steel mills, food and beverage processing facilities, power generation, and other flow-process industries. The company was formerly known as Xanser Corporation and changed its name to Furmanite Corporation in May 2007. Furmanite Corporation was founded in 1952 and is headquartered in Richardson, Texas..
Gerdau SA (NYSE:GGB) - Gerdau S.A. engages in the production and commercialization of steel products worldwide. The company offers crude steel products, which include billets that are used to manufacture wire rods, rebars, and merchant bars; blooms for use in the manufacture of springs, forged parts, heavy structural shapes, and seamless tubes; and slabs, which are used in the steel industry for the rolling of various flat rolled products, as well as used to produce hot and cold rolled coils, heavy slabs, and profiles. Its long rolled products include rebars, merchant bars, and profiles, which are primarily used in the construction and manufacturing industries; and drawn products comprise barbed and barbless fence wires, galvanized wires, fences, concrete reinforcing wire mesh, nails, and clamps for manufacturing, construction, and agricultural sectors. The company also offers special and stainless steel products used in tools and machinery, chains, fasteners, railroad spikes, and special coil steel, as well as special sections, such as grader blades, smelter bars, light rails, super light I-beams, and elevator guide rails. In addition, it provides flat products, such as hot and cold steel coils, heavy plates, and profiles; and resells flat steel products manufactured by other Brazilian steel producers. The company was founded in 1901 and is based in Porto Alegre, Brazil. Gerdau S.A. is a subsidiary of Metal rgica Gerdau S.A..
Auxilium Pharmaceuticals Inc (NASDAQ:AUXL) - Auxilium Pharmaceuticals, Inc., a specialty biopharmaceutical company, together with its subsidiaries, engages in developing and marketing pharmaceutical products primarily in the United States. It markets Testim, a testosterone gel for the treatment of hypogonadism; and XIAFLEX (collagenase clostridium histolyticum), an injectable collagenase enzyme for the treatment of Dupuytren s contracture in adult patients with a palpable cord. The company is also developing XIAFLEX, which is in Phase III clinical trial for the treatment of Peyronie s disease, in Phase IIa clinical trial for the treatment of Adhesive Capsulitis (frozen shoulder syndrome), and in Phase Ib clinical trial for the treatment of edematous fibrosclerotic panniculopathy indications. In addition, it has rights to pursue various other indications for XIAFLEX. The company sells its products to wholesale drug distributors, specialty pharmacies, specialty distributors, and chain drug stores. Auxilium Pharmaceuticals, Inc. was founded in 1999 and is headquartered in Malvern, Pennsylvania..
Momenta Pharmaceuticals Inc (NASDAQ:MNTA) - Momenta Pharmaceuticals, Inc., a biotechnology company, specializes in the structural characterization, process engineering, and biologic systems analysis of complex molecules. These complex molecules include polysaccharides, polypeptides, and proteins and antibodies. Its technologies are used to develop a product portfolio of complex generic, follow-on biologic, and novel therapeutics. It offers Enoxaparin sodium injection, a generic version of Lovenox to prevent and treat deep vein thrombosis, and to support the treatment of acute coronary syndromes (ACS). The company s products also include M356, a generic version of Copaxone under FDA review for the reduction of the frequency of relapses in patients with relapsing-remitting multiple sclerosis; M402, a novel polysaccharide-based drug candidate that is in development as a potential anti-cancer agent; Adomiparin, a polysaccharide-based drug candidate, which supports the treatment of ACS; and interchangeable biologics and biosimilar versions of marketed therapeutic proteins. Momenta Pharmaceuticals, Inc. has collaboration agreements with Sandoz AG; Baxter International, Inc.; Baxter Healthcare Corporation; and Baxter Healthcare SA. The company was formerly known as Mimeon, Inc. and changed its name to Momenta Pharmaceuticals, Inc. in September 2002. Momenta Pharmaceuticals, Inc. was founded in 2001 and is based in Cambridge, Massachusetts..
SqueezeTrigger.com has built a massive database that collects, analyzes and publishes multiple proprietary trading strategies that predict price moves in stocks, commodities and currencies. The data has then been integrated into an automated trading platform which can be used to connect to a live online broker and automate your trading of each of the strategies highlighted. It is extremely powerful with lightening fast execution at a very low price. Both the trading software and SqueezeTrigger data feed are available at http://www.squeezetrigger.com
www.squeezetrigger.com monitors trading in all US stocks in real time and maintains massive databases of short sale and naked short sale time and sales data, short squeeze SqueezeTrigger prices, market maker price movements, shareholder data, statistical data on earnings, sector correlation, seasonality, hedge fund trading strategies, comparable valuations. Reports include:
REGULATORY & COMPLIANCE NEWS
Friction Factor -- market maker surveillance system tracking Level II market makers in all stocks to determine Price Friction and compliance with new "Fair Market Making Requirements".
RegSHO Naked Shorts -- tracks EVERY failure to deliver in all US stocks and tracks all Threshold Security Lists daily for which stocks have naked shorts that are not in compliance with Regulation SHO.
INVESTMENTS & TRADING
SqueezeTrigger -- 25 billion cell database tracks EVERY short sale (not just total short interest) in all US stocks and calculates volume weighted price that a short squeeze will begin in each stock.
Earnings Edge -- predicts probability, price move and length of move before and after all US stock earnings reports.
Seasonality -- predicts probability, price move and length of move based on exact time of year for all US stocks.
Group Trader -- tracks sector rotation and stock correlation to its sector and predicts future moves in ALL sectors and industry groups.
Pattern Scan -- automates tracking of every technical pattern and predicts time and size of move in all stocks.
GATS (Global Automated Trading System) -- tracks all known trading strategies and qualifies and quantifies which are working best in real time.
WWW.SQUEEZETRIGGER.COM is a service designed to help bonafide shareholders of publicly traded US companies fight short selling. SqueezeTrigger.com has built a proprietary database that uses Threshold list feeds and short sale time and sale data from NASDAQ, AMEX and NYSE to generate detailed and useful information to combat the short selling problem. For the first time, actual trade by trade data is available to the public that shows the attempted size, actual size, price and average value of short sales in stocks that have been shorted. This information is valuable in determining the precise point at which short sellers go out-of-the-money and start losing on their short trades.
SQUEEZETRIGGER.COM has built a massive database that collects, analyzes and publishes a proprietary SqueezeTrigger for each stock that has been shorted. The SqueezeTrigger database of nearly 2.5 billion short sale transactions goes back to January 1, 2005 and calculates the exact price at which the Total Short Interest is short in each stock. This data was never before available prior to January 1, 2005 because the Self Regulatory Organizations (primary exchanges) guarded it aggressively. After the SEC passed Regulation SHO, exchanges were forced to allow data processors like SqueezeTrigger.com to access the data.
The SqueezeTrigger database collects individual short trade data on over 7,000 NYSE, AMEX and NASDAQ stocks and general short trade data on nearly 8,000 OTCBB and PINKSHEET stocks. Each month the database grows by approximately 50,000,000 short sale transactions and provides investors with the knowledge necessary to time when to buy and sell stocks with outstanding short positions. By tracking the size and price of each montha'a"s short transactions, SQUEEZETRIGGER.COM provides institutions, traders, analysts, journalists and individual investors the exact price point where short sellers start losing money and a short squeeze can begin.
All material herein was prepared by SQUEEZETRIGGER.COM, based upon information believed to be reliable. The information contained herein is not guaranteed by SQUEEZETRIGGER.COM to be accurate, and should not be considered to be all-inclusive. The companies that are discussed in this opinion have not approved the statements made in this opinion.
Occassionally companies pay $995.00 to purchase data for information provided in reports issued by BUYINS.NET, a company affiliated with SQUEEZETRIGGER.COM. The data service can be cancelled at any time. This opinion contains forward-looking statements that involve risks and uncertainties. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. SQUEEZETRIGGER.COM is not a licensed broker, broker dealer, market maker, investment banker, investment advisor, analyst or underwriter. Please consult a broker before purchasing or selling any securities viewed on or mentioned herein. SQUEEZETRIGGER.COM will not advise as to when it decides to sell and does not and will not offer any opinion as to when others should sell; each investor must make that decision based on his or her judgment of the market.
SQUEEZETRIGGER.COM and SQUEEZETRIGGER are intended for use by stock market professionals. As a member, visitor, or user of any kind, you accept full responsibilities for your investment and trading actions. The contents of SQUEEZETRIGGER.COM, including but not limited to all implied or expressed views, opinions, teachings, data, graphs, opinions, or otherwise are not predictions, warranty, or endorsements of any kind. Please seek stock market advice from the proper securities professional, or investment advisor.
By visiting SQUEEZETRIGGER.COM or using any data or services, you agree to assume full responsibility for the decisions or actions that you undertake. Global Automated Trading Systems, LLC, its owner(s), operators, employees, partners, affiliates, advertisers, information providers and any other associated person or entity, shall under no circumstances be held liable to the user and/or any third party for loss or damages of any kind, including but not limited to trading losses, lost trading opportunity, direct, indirect, consequential, special, incidental, or punitive damages. As a user, you agree that any damages collected shall not exceed the amount paid to SQUEEZETRIGGER.COM and/or its owners. As a website user, you agree that any and all legal matters of any kind are to be reviewed and handled in their entirety within the State of California only. By using the services of this website, you are consenting to the terms as outlined, and forfeit all legal jurisdictions in any other State.
Past performance is not a guarantee of future outcomes. Any and all examples are hypothetical and should not be considered a guarantee or endorsement of such trading activity. SQUEEZETRIGGER.COM does not take responsibility for problems of any kind, including but not limited to issues with operations, data accuracy or completeness, contacting issues, technical issues, and timeliness. SQUEEZETRIGGER.COM places great integrity on the data collected and distributed. This information is deemed reliable, but not guaranteed. All information and data is provided "as is" without warranty or guarantee of any kind.
Please seek investment and/or trading advice, council, information or services from a securities professional. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and SQUEEZETRIGGER.COM undertakes no obligation to update such statements.
This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.
"Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected", "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a companies' annual report on Form 10-K or 10-KSB and other filings made by such company with the SEC.
Thomas Ronk, CEO
SqueezeTrigger is a registered trademark, Reg. No. 3,120,641
((M2 Communications disclaims all liability for information provided within M2 PressWIRE. Data supplied by named party/parties. Further information on M2 PressWIRE can be obtained at http://www.presswire.net on the world wide web. Inquiries to email@example.com)).